Ph I Data For Aronex' New Anthracycline
Aronex Pharmaceuticals' novel anthracycline, annamycin, has been foundto have a favorable side-effect profile at its maximum tolerated dose, according to Phase I data presented at ASCO. Doses ranged from 3mg/m2 to 240mg/m2.
"At any of the doses evaluated, there was no definite evidence of cardiotoxicity or mucositis," said the company. Both these effects are common problems with currently-used anthracyclines such as doxorubicin. Nausea and alopecia were minimal, and the dose-limiting effect was thrombocytopenia. Aside from its greater tolerability, annamycin can be used in multidrug-resistant tumors, according to preclinical data.
Aronex' chief medical officer David Gordon said that now that the MTD has been identified, the drug is entering a Phase II trial in patients with anthracycline-resistant breast cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze